AU2728301A - Combination therapy for the treatment of inflammatory and respiratory diseases - Google Patents

Combination therapy for the treatment of inflammatory and respiratory diseases

Info

Publication number
AU2728301A
AU2728301A AU27283/01A AU2728301A AU2728301A AU 2728301 A AU2728301 A AU 2728301A AU 27283/01 A AU27283/01 A AU 27283/01A AU 2728301 A AU2728301 A AU 2728301A AU 2728301 A AU2728301 A AU 2728301A
Authority
AU
Australia
Prior art keywords
inflammatory
treatment
combination therapy
respiratory diseases
respiratory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27283/01A
Inventor
William Louis Macias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2728301A publication Critical patent/AU2728301A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
AU27283/01A 2000-01-06 2000-12-22 Combination therapy for the treatment of inflammatory and respiratory diseases Abandoned AU2728301A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17472300P 2000-01-06 2000-01-06
US60174723 2000-01-06
PCT/US2000/034262 WO2001049323A1 (en) 2000-01-06 2000-12-22 Combination therapy for the treatment of inflammatory and respiratory diseases

Publications (1)

Publication Number Publication Date
AU2728301A true AU2728301A (en) 2001-07-16

Family

ID=22637250

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27283/01A Abandoned AU2728301A (en) 2000-01-06 2000-12-22 Combination therapy for the treatment of inflammatory and respiratory diseases

Country Status (5)

Country Link
EP (1) EP1259260A1 (en)
JP (1) JP2003519198A (en)
KR (1) KR20030016214A (en)
AU (1) AU2728301A (en)
WO (1) WO2001049323A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006096668A (en) * 2002-11-08 2006-04-13 Ono Pharmaceut Co Ltd Medicine comprising combination of elastase inhibitor with enzyme inhibitor of blood coagulation system and/or fibrinolysis system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0143565B1 (en) * 1988-06-13 1998-07-15 사노 가즈오 Derivatives of p-substituted phenyl ester of pivalic acid
ES2377223T3 (en) * 1994-04-01 2012-03-23 Eli Lilly And Company [[3- (2-Amino-1,2-dioxoethyl) -2-ethyl-1- (phenylmethyl) -11H-indole-4-IL] oxy] acetic acid methyl ester as an inhibitor of sPLA2
WO1998018464A1 (en) * 1996-10-30 1998-05-07 Eli Lilly And Company Substituted tricyclics
WO2000015207A2 (en) * 1998-09-15 2000-03-23 Naeja Pharmaceutical Inc. Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)

Also Published As

Publication number Publication date
KR20030016214A (en) 2003-02-26
WO2001049323A1 (en) 2001-07-12
EP1259260A1 (en) 2002-11-27
JP2003519198A (en) 2003-06-17

Similar Documents

Publication Publication Date Title
IL169338A0 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
AU7186501A (en) Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
PL362711A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AU2003264282A1 (en) Phenethanolamine derivatives and their use in the treatment of respiratory diseases
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU1227302A (en) System and method for optimizing drug therapy for the treatment of diseases
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
EP1392292A4 (en) Pyranoindazoles and their use for the treatment of glaucoma
AU6083899A (en) Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
GB0004531D0 (en) The treatment of respiratory diseases
AU3840802A (en) Methods and compositions for the treatment of diseases of the eye
AU5937901A (en) Combination therapy of respiratory diseases using antibodies
AUPQ344799A0 (en) Treatment of respiratory diseases and infections
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2001249262A1 (en) Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
AU2908501A (en) Combination therapy for the treatment of inflammatory and respiratory diseases
AU5611701A (en) Agent for the diagnosis and therapy of viral diseases
AU2728301A (en) Combination therapy for the treatment of inflammatory and respiratory diseases
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU1405001A (en) Treatment of diseases
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases
AU2002224905A1 (en) Use of bromelain for the treatment of inflammatory diseases and for adjuvant therapy during wound healing processes

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase